ZFHX3
Overview
ZFHX3 (Zinc Finger Homeobox 3, also known as ATBF1) is a large transcription factor containing multiple AT-motif binding domains and zinc finger motifs. ZFHX3 has been implicated as a tumor suppressor in prostate cancer, where recurrent mutations suggest loss-of-function contributes to CRPC progression. It is one of nine significantly mutated genes identified in lethal prostate cancer exome sequencing, indicating a driver role in advanced disease.
Alterations observed in the corpus
- ZFHX3 identified as one of nine significantly mutated genes (FDR ≤ 0.10) in prostate cancer WES of 112 tumors (Michigan cohort, including 50 lethal CRPCs); mutations present in castration-resistant disease PMID:22722839
- ZFHX3 mutated in 7/402 (1.7%, q=0.79) PTCs; near-significant putative tumor suppressor in PTC; does not meet the q<0.1 threshold for SMG designation but represents a candidate dark-matter driver. PMID:25417114
Cancer types (linked)
Co-occurrence and mutual exclusivity
Therapeutic relevance
- No direct targeted therapies identified for ZFHX3-mutant prostate cancer in the corpus. Given its role alongside chromatin modifiers in CRPC, pathway context may offer indirect therapeutic opportunities.
Open questions
- The precise tumor suppressor mechanism of ZFHX3 in prostate cancer (transcriptional targets, interaction with AR signaling) is not characterized in the corpus.
- Whether ZFHX3 mutations are more prevalent in CRPC vs. localized prostate cancer requires direct comparison in larger cohorts.
Sources
- PMID:22722839 — Prostate cancer WES, 112 tumors, Michigan cohort
This page was processed by entity-page-writer on 2026-05-06. - PMID:25417114
This page was processed by wiki-cli on 2026-05-14.